AMD3100 leads to significant lymphocyte mobilization into the peripheral blood. (A) CD34 cells were quantified based on the number of CD45-FITC lymphocytes expressing CD34-PE per microliter of blood before (n = 3) and 2, 4, and 6 hours after mobilization (n = 6 for each time point). (B-F) The total peripheral blood WBC (B), ANC (C), lymphocyte count (D), fold change in the lymphocyte count (E), and the percentage of the whole blood accounted for by lymphocytes (F). (B-F) Data were collected at baseline and at 2, 4, and 6 hours after treatment with AMD3100 (n = 6 for each time point). Red squares represent mobilization with G-CSF alone; blue triangles, mobilization with AMD3100 alone; and green circles, mobilization with G-CSF + AMD3100. Error bars represent SEM. Statistical analysis was performed by pooling the data from 2 separate experiments in which groups of 3 animals each were treated with either G-CSF alone, AMD3100 alone, or G-CSF + AMD3100. Values obtained with AMD3100 alone, G-CSF alone, or G-CSF + AMD3100 at baseline and at 2, 4, and 6 hours after mobilization were log-transformed and then subjected to ANOVA and posthoc Tukey testing. ANOVA statistics comparing all 3 treatment groups are shown below the x-axis. (A-E) Posthoc Tukey statistics comparing AMD3100 alone with G-CSF alone (blue symbols), G-CSF + AMD3100 alone with G-CSF alone (green symbols), or G-CSF + AMD3100 with AMD3100 (black brackets) are shown. (F) Posthoc Tukey statistics comparing AMD3100 alone with G-CSF alone or AMD3100 alone with G-CSF + AMD3100 are shown in red or green symbols, respectively. ns indicates not significant (P > .1). ^P < .1. *P < .05. **P < .01. ***P < .001.